Kudos Pharmaceuticals Limited

Cancer Research Technology Limited

Maybridge Limited

Astrazeneca Ab

Marc Geoffrey Hummersone

Keith Allan Menear

Niall Morrison Barr Martin

Graeme Cameron Murray Smith

Roger John Griffin

Laurent Jean Martin Rigoreau

Sylvie Gomez

Bernard Thomas Golding

David Richard Newell

Ian Robert Hardcastle

Xiao-Ling Fan Cockcroft

Nicola Curtin

Muhammad Hashim Javaid

Hilary Alan Calvert

Kappusamy Saravanan

Frank Kerrigan

Xiao-ling Fan Cockcroft

Ian Timothy Williams Matthews

Heather Mary Ellen Duggan

Karine Fabienne Malagu

David Alan Rudge

Craig Anthony Roberts

Mark Frigerio

Kevin Blades

Carlos Fenandez Lence

Marine Desage-El Murr

Gesine Johanna Hermann

Stephen P Kudos Pharmaceuticals Ltd Jackson

Niall M B Kudos Pharmaceuticals Ltd Martin

Graeme C M Kudos Pharmaceuticals Ltd Smith

Alan Y K Kudos Pharmaceuticals Ltd Lau

Mark J Kudos Pharmaceuticals Ltd O'CONNOR

Xiao-Ling Fan Chemovation Ltd Cockcroft

A compound of the formula (I): wherein:A and B together represent an optionally substituted, fused aromatic ring; X and Y are selected from CH and CH, CF and CH, CH and CF and N and CH respectively; Ris selected from H, Calkyl; and Ris selected from Calkyl, Cheterocyclyl and Caryl, which groups are optionally substituted; or Rand Rtogether with the carbon and oxygen atoms to which they are attached form a spiro-Coxygen-containing heterocyclic group, which is optionally substituted or fused to a Caromatic ring.

Phthalazinone derivatives

A compound of the formula (I): wherein: where Yis selected from CH and N, Yis selected from CH and N, Yis selected from CH, CF and N; and where Q is O or S; wherein

A compound of formula I: and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein: Rand Rare independently selected from hydrogen, an optionally substituted Calkyl group, Cheterocyclyl group, or Caryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; Q is &#x2014;NH&#x2014;C(&#x2550;O)&#x2014; or &#x2014;O&#x2014;; Y is an optionally substituted Calkylene group; X is selected from SRor NRR, wherein, R, or Rand Rare independently selected from hydrogen, optionally substituted Calkyl, Caryl, or Cheterocyclyl groups, or Rand Rmay together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; if Q is &#x2014;O&#x2014;, X is additionally selected from &#x2014;C(&#x2550;O)&#x2014;NRR, wherein Rand Rare independently selected from hydrogen, optionally substituted Calkyl, Caryl, or Cheterocyclyl groups, or Rand Rmay together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; and if Q is &#x2014;NH&#x2014;C(&#x2550;O)&#x2014;, &#x2014;Y&#x2014;X may additionally be selected from Calkyl.

DNA-PK inhibitors

Compounds of formula I: wherein A, B and D are respectively selected from the group consisting of:

A compound of formula I: and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein:

ATM inhibitors

Compounds of formula I:A-B-C&#x2003;&#x2003;(I)and isomers, salts, solvates, chemically protected forms, and prodrugs thereof are provided, wherein variables A, B and C are defined herein and wherein such compounds act as mTor inhibitors.

mTOR inhibitor compounds

A compound of formula I: and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein: Rand Rtogether form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; and Ris selected from hydrogen, an optionally substituted Calkyl group, an optionally substituted Cheterocyclyl group, an optionally substituted Caryl group, an acyl group, an ester group and an amido group, and its use as a pharmaceutical.

Growing community of inventors

Cambridge, United Kingdom

Marc Geoffrey Hummersone